Induction of apoptosis in cancer cells with wild-type EGFR or tyrosine kinase domain-mutated EGFR by cetuximab and gefitinib

<p><b>Copyright information:</b></p><p>Taken from "Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1α"</p><p>http://www.molecular-cancer.com/content/6/1/63</p><p>Molecular Cancer 2007;6():63-63.</p><p>Published online 11 Oct 2007</p><p>PMCID:PMC2117021.</p><p></p> Cells from each line were left untreated or were treated with vehicle (DMSO), 5 nM cetuximab, or 0.5 μM gefitinib in a medium containing 0.5% FBS. After 16 hours of treatment, the cells were harvested and lysed for quantitative apoptosis measurement by () an enzyme-linked immunosorbent assay, as described in the Methods section, and () Western blot analysis with anti-PARP antibodies. *P < 0.05, **P < 0.01 compared with corresponding controls